MKI67 and Miyoshi myopathy: Given the potential use of PD-L1 expression as a biomarker for adjuvant immunotherapy in MM and ongoing studies assessing combination immunotherapy + chemotherapy, Ki67 level and PD-L1 expression may serve as a combined biomarker for benefit of adjuvant therapy (10).